Our goal at Beacon Genomics is to provide broad access to our industry-leading methods for defining the safety and genome-wide specificity of gene editing nucleases. Beacon Genomics was founded in late 2015 and has exclusively
licensed GUIDE-Seq (Genome-wide Unbiased Identification of DSBs Enabled by Sequencing) and CIRCLE-Seq (Circularization for In Vitro Identification of Cleavage Effects) methods originally developed in the lab of Professor J. Keith Joung at Massachusetts General Hospital and Harvard Medical School. We are commercializing both services and kits to meet the growing demands of customers in the therapeutics, life
science tools, reagents, and academic spaces.
Beacon Genomics core technologies can be used to optimize safety of genome editing therapies by discovering potential sites of off-target editing activity and defining conditions that minimize undesired off-target mutagenesis. These technologies were initially developed in the lab of Professor J. Keith Joung at Massachusetts General Hospital and Harvard Medical School.